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Abstract 
 
HER2(human epidermal growth receptor 2) is recognized as an oncogenic driver gene, 
and inhibition of HER2 is expected to lead the antitumor effect. Although HER2-targeting 
antibodies and a HER2-directing antibody-drug conjugate (ADC), are approved for use 
in patients with HER2-overexpressing breast cancers, there is still a need for effective 
therapies in patients refractory to those therapies. Lapatinib, a small molecule, non-
covalent, reversible HER2/EGFR dual inhibitor, is available in treatment for HER2 
overexpressed breast cancer. However, the clinical result is not satisfactory, due to the 
insufficient potency. Afatinib and neratinib are small molecule, covalent-binding, pan-
ERBB inhibitors. The issue of these covalent pan-ERBB inhibitors is a severe diarrhea 
due to the EGFR inhibition. Therefore, HER2 selective, potent inhibitor is desired to 
improve the clinical benefit of cancer patients. To provide a novel therapeutic option for 
cancer patients, the author aimed to screen the compound and set up the screening flow. 
The author identified a candidate compound, TAS0728 and evaluated the antitumor 
profile of the identified novel compound in various preclinical models whether the 
compound can go into the clinical setting. Furthermore, the author investigated the 
antitumor mechanism of the inhibitor. 
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Firstly, to elucidate the antitumor profile and mode of action of the inhibitor, the 
author investigated the binding mode, pharmacodynamics of the compound in cancer 
cells and tumors. Unlike lapatinib, TAS0728 covalently bound to HER2 and inhibited the 
kinase activity irreversibly. In HER2amplified SKBR3 cells, TAS0728 exhibited a 
sustained and robust inhibition of the HER2 signaling pathway. Notably, in the TAS0728 
treated group, apoptosis induction associated with BIM (an apoptosis inducer) 
stabilization was observed. Consistently, TAS0728 induced tumor shrinkage associated 
with enhanced apoptosis marker induction in mouse xenograft models bearing NCI-N87 
(HER2 activated gastric cancer).  
Secondly, the author investigated selectivity of the compound to address the risk of 
the side-effect. In an enzyme kinase panel of 386 kinases, TAS0728 showed a potent 
inhibitory activity for wild type HER2, while little activity against the majority of other 
kinases including EGFR. Cellular pharmacodynamic evaluation in HER2 amplified 
SKBR3 cells and EGFR amplified A431 cells revealed that TAS0728’s selectivity 
between HER2 and EGFR was higher than afatinib. In growth inhibition assays with 
various cell lines, TAS0728 exhibited antiproliferative activity only against HER2 
activated cells across various cell lines.  
Lastly, the author investigated whether TAS0728 had antitumor activity for tumor 
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models resistant to anti-HER2 ADC, T-DM1. In a NCI-N87 xenograft model, although 
T-DM1 initially induced tumor shrinkage, T-DM1 was no longer effective once the tumor 
started to grow after T-DM1 treatment. In contrast, switching to TAS0728 treatment 
induced tumor regression again. Furthermore, in a patient derived xenograft model 
derived from a HER2 over-expressed breast cancer patient resistance to 
trastuzumab/pertuzumab-based therapy, T-DM1 and other chemotherapies, TAS0728 
exhibited the potent antitumor effect. 
The author has revealed that TAS0728 is an orally available, potent antitumor agent 
for HER2 activated tumors. The author also clarified the mode of action of the antitumor 
effect. TAS0728 is a promising therapeutic option for HER2 activated cancer and would 
be expected to have an improved therapeutic window compared to current HER2 
inhibitors. The assessment of TAS0728 in human is ongoing in the US and EU. 
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Abbreviation Definition 
 
QOL: quality of life 
HER2: Human epidermal growth receptor 2 
EGFR: Epidermal growth factor receptor 
HER3: Human epidermal growth receptor 3 
HER4: Human epidermal growth receptor 4 
ERK: extracellular signal-regulated kinase 
AKT: protein kinase B 
BMX: bone marrow tyrosine kinase on chromosome X 
BLK: tyrosine protein kinase Blk 
JAK3: Junus kinase 3 
SLK: STE20-like serine/threonine-protein kinase 
LOK: Serine Threonine kinase 10 
MAP4K5: mitogen-activated protein kinase kinase kinase kinase 5 
TXK: tyrosine-protein kinase 
BTK: Bruton’s tyrosine kinase 
ACK1: Activated Cdc42 kinase 
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TNIK: TRAF2 and NCK-interacting protein kinase 
TEC: Tyrosine-protein kinase 
MAP4K3: Mitogen-activated protein kinase kinase kinase kinase 3 
DDR1: Discoidin domain receptor tyrosine kinase 1 
ITK: interleukin (IL)-2-inducible T-cell kinase 
PLK4: polo-like kinase 4 
PI3K: phosphoinositide 3’-kinase 
FOXO3A: Forked box 3A 
BIM: B-cell lymphoma 2 interacting mediator of cell death 
PARP: Poly（ADP-ribose）polymerase 
ALK: Anaplastic lymphoma kinase 
TRK: tropomyosin-related kinase 
PDX：Patient Derived Xenograft 
AUC：Area under the plasma concentration-time curve  
Cmax: Maximum observed plasma concentration 
CYP: Cytochrome P450 
DMSO: Dimethyl sulfoxide 
GI50:50% growth inhibition 
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GI: Gastrointestinal 
IC50: 50% inhibitory concentration 
LC-MS: Liquid chromatography-mass spectrometry 
ADCC: Antibody-Dependent-Cellular-Cytotoxicity 
FDA: Food and Drug Administration 
ADC: Antibody drug conjugate 
TKI: tyrosine kinase inhibitor 
DLT: dose limiting toxicity 
MBC: metastatic breast cancer 
BWC: body weight change 
ATP: adenosine triphosphate 
MW: molecular weight 
SD: standard deviation 
SEM: standard error of mean 
ELIZA: Enzyme-Linked ImmunoSorbent Assay 
TGI: tumor growth inhibition 
QD/q.d.: quaque die 
p.o.: per os 
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Chapter 1: Introduction 
 
1.1 General introduction 
Medicine is crucial for therapy of most diseases. To date, various medicines has 
contributed to patient therapy and improved their quality of lives s. For example, although 
tuberculosis used to be a life-threatening disease [1], it is no longer incurable thanks to 
medicines. Moreover, new drugs have dramatically improved medical treatment for some 
diseases, including hypertension and diabetes [2]. However, there remain illnesses for 
which medical treatment is not effective.  
Cancer, presently a major cause of death of human all over the world [3], requires better 
clinical therapies and new medicines. Although many developed chemotherapeutic agents 
result in some clinical benefit, these agents have severe side effects [4]. Recent 
development of molecular-targeted therapy such as ALK inhibitors has proved clinically 
effective, with fewer side effects [5]. The purpose of molecular-targeted drugs is to attack 
only cancer cells, without affecting normal tissues. A number of drug targets, or 
oncogenes, have been identified, and inhibitors are being developed [6]. However, 
complete remission remains difficult to achieve for advanced solid tumors, and 
development of new medicines is still required to improve treatment. Medicine is crucial 
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to disease treatment, and less toxic, more effective medicines are needed. 
Kinases involve to various biological processes though modulating signaling pathways 
and are recognized as a promising drug target for various diseases[7].  To overcome the 
diseases, many kinase inhibitors have been developed and approved for a therapy against 
diseases. However, not a few failures of the development have also been reported. The 
reasons for the failure cases are considered to be adverse effect or the unsatisfactory 
efficacy against the diseases in pre-clinical studies or clinical settings.  A novel kinase 
inhibitor that shows the sufficient efficacy and less adverse effect may overcome the 
difficulties of the drug development. 
  
1.2 Biology of HER2 kinase  
HER2 is a receptor tyrosine kinase, and is a member of ERBB(v-erythroblastic 
leukemia viral oncogene homolog) family kinases including EGFR, HER2, HER3, and 
HER4[8]. HER2 is a 185 kDa protein composed of extracellular, transmembrane, and 
intracellular domains. The extracellular domain, which is consider to function to form 
the dimerization, consists of four subdomains, domain I, II, III, and IV [8]as shown in 
Figure 1-1. The intracellular domains of HER2 possess the catalytic, kinase domain, 
which has 88% identity to EGFR[9]. Abnormalities of HER2 including overexpression, 
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amplification and mutation have been reported in various cancers [10, 11]. For example, 
more than 10% of breast cancer patients were diagnosed as HER2 amplified breast 
cancer a year in the US as shown in Table 1-1. HER2 dimerization induces activation of 
HER2 signal transduction associated with the enhanced survival and cell growth signal 
in cancer cells. HER2 has been recognized as an oncogenic driver and potential 
therapeutic target for treatment of various cancers[12]. To date, various HER2 targeted 
therapies have been developed, and some of them have approved by FDA and used for 
the therapy[13]. The current status of development of HER2 targeted therapies were 
summarized in the next section. 
 
1.3 HER2 targeted therapy 
1.3.1 HER2 targeted antibodies and antibody-drug conjugate (ADC) 
Trasutuzumab is a humanized monoclonal antibody to target HER2 which binds to the 
domain IV, an extracellular domain of HER2. Trastuzumab inhibits HER2-mediated 
proliferation, and the proposed mechanism of actions include activating antibody-
dependent cellular cytotoxicity (ADCC), attenuating HER2 signaling, and inhibiting of 
tumor angiogenesis, etc[14]. Trastuzumab has shown the survival benefit for HER2-
positive breast cancer patients both in advanced metastatic cancer and in early stage of 
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the disease as adjuvant therapy.  Pertuzumab is another humanized monoclonal antibody 
and binds to the domain II, dimerization domain of HER2. Pertuzumab in combination 
with trastuzumab and docetaxel improved the clinical outcome of the patients with 
metastatic HER2-positive breast cancer in CLEOPATRA trial, and was approved to be 
used in 1st line treatment [15]. However, acquired resistance to the 
trastuzumab/pretuzumab combination has developed with time, which needs to be 
overcome. 
T-DM1, a conjugate of trastuzumab and a cytotoxic payload (DM1, derivative 
maytansine), is used for the treatment of 2nd line therapy for HER2-overexpressed 
metastatic breast cancer. DM1 which acts as a potent anti-microtubule agent inhibiting 
the polymerization of tubulin[16]. The internalized DM1 into the cells binds to the beta 
subunit of tubulin at the same place as the vinca alkaloids, resulting in the cell cycle arrest 
and significant cell death of target cancer cells. The phase 3 studies including EMILIA 
[17], THERESA[18] showed that T-DM1’s superior efficacy to capecitabine plus 
lapatinib or treatment of physicians’ choice. Although primary resistance of HER2 
overexpressed breast cancer patient to T-DM1 appears to be infrequent, most of patients 
ultimately developed acquired drug resistance. However, the mechanism of resistance is 
still unclear.  
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 1.3.2 Small molecule tyrosine kinase inhibitor (TKI) 
1.3.2.1 Lapatinib 
Lapatinib (C29H26ClFN4O4S. (C7H8O3S)2. H2O), a small molecule reversible dual kinase 
inhibitor which interrupts the HER2 and EGFR[19]. The mechanism of the kinase 
inhibition is ATP-competitive manner. Lapatinib is approved to be used in combination 
with capecitabine for the treatment of HER2-overexpressing breast cancer patients who 
have received prior therapy including an anthracycline, a taxane, and trastuzumab [19]. 
Although HER2 is an oncogenic driver gene, the response rate of the tumor to lapatinib 
as a monotherapy was less than 10% in chemotherapy-refractory HER2-positive breast 
cancer (Figure 1-3). Compared to other molecular targeting therapies such as ALK 
inhibitors [20], TRK inhibitor [21], and EGFR inhibitors [22], the lapatinib’s response 
rate was much lower. A previous preclinical study that reported the resiliency of the 
HER2/HER3 signaling pathway provides insights into the poor clinical outcomes 
associated with lapatinib therapy [23]. Indeed, the buffering activity of the HER2/HER3 
pathway was shown to be related to the HER3 reactivation mechanism, and full 
inactivation of HER2 with high-dose lapatinib regimen may vanquish the negative 
feedback reactivation of HER3. Consistently, extremely high doses of lapatinib as a 
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monotherapy with 5-day intermittent dosing elicited dramatic clinical responses, although 
concomitant treatment of a CYP inhibitor was required to achieve and keep high plasma 
concentrations [24]. Therefore, robust inhibition of HER2 signal may result in dramatic 
responses in HER2-addicted tumors. 
 
1.3.2.2 Afatinib & neratinib 
Afatinib (C24H25ClFN5O3・2C4H4O4) is an oral small molecule inhibitor targeting EGFR, 
HER2, and HER4. Afatinib covalently binds to ERBB kinases and irreversibly inhibits 
those target kinase. Results from a single arm, phase II study of afatinib for HER2-
positive MBC progressing post trastuzumab (N=41) showed 4 partial responses among 
35 patients. The common all-grade treatment related adverse events included diarrhea and 
rash [25]. LUX-Breast1, phase3 trial has been conducted to compare the regimens of 
vinorelbine plus either afatinib or trastuzumab for HER2-positive MBC in patients who 
failed one trastuzumab-containing regimen as first-line treatment of MBC or as adjuvant 
therapy [26]. However, the study was halted early due to unfavorable risk-benefit analysis 
from the independent data monitoring committee.   
Neratinib (C30H29ClN6O3) is also an orally available, covalent-binding, small molecule 
inhibitor targeting EGFR, HER2, and HER4. A phase II open label study in locally 
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advanced breast cancer showed 24% of objective response rate for patients with prior 
trastuzuamb treatment, and 56% of objective response rates for patients with no prior 
trastuzuamb, respectively [27]. Diarrhea was the most common grade 3(increase of 
greater than 7 stools/day over baseline) or 4(Life-threatening) toxic effect of neratinib. 
Based on the results from ExteNET trial in adjuvant trastuzumab-pretreated early-stage 
breast cancer, neratinib was approved by FDA to be used in the adjuvant setting for 
HER2-positive metastatic breast cancer [28]. 
To date, various covalent-binding kinase inhibitors against HER2 have been developed 
and have been shown the antitumor effect in preclinical models and clinical settings [29, 
30]. However, these reported HER2 inhibitors are not selective for HER2 and instead act 
as pan-ERBB kinase inhibitors that inactivate the activity of ERBB family kinases, 
including EGFR. Although EGFR is a well-established therapeutic target in cancers, 
inhibition of this EGFR signaling in normal tissues can associate with dose-limiting 
gastrointestinal (GI) issues (Table 1-2) and rashes, particularly diarrhea to the level of 
grade 3 or 4 toxicity [31]. Therefore, the high selectivity for HER2 inhibition excluding 
EGFR may allow for more effective dosing to vanquish the resiliency of the HER2/HER3 
pathway in HER2-activated cancers and improve the clinical response rates of 
conventional HER2 TKIs. However, identification of HER2-selective covalent inhibitors 
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is still challenging due to the high structural similarity between HER2 and EGFR (Figure 
1-3).  
 
1.5 Screening flow of a next generation HER2 selective inhibitor 
TAIHO pharmaceutical has been developing various kinase inhibitors.  Leveraging the 
accumulated experiences and knowledge in TAIHO, I aimed to develop a next generation 
HER2 kinase inhibitor, and tried to screen lead compounds to develop a covalent-binding, 
selective HER2 inhibitor.  
To screen the compound, the original evaluation flow was established as described in 
Figure 1-4. Firstly, to evaluate the HER2/EGFR selectivity of hundreds of candidate 
kinase inhibitory compound, HER2 and EGFR recombinant enzymes were used to 
evaluate the kinase inhibitory activity. Based on the Structure-activity relationship  
information obtained from the assays, the kinase binding domain of the compound was 
designed to distinguish the difference of steric hindrance between EGFR and HER2 
(Figure 1-3). Through the screening with the recombinant proteins, three types of primary 
hit compounds were obtained.  
Next, to confirm the inhibitory activity for HER2 in cancer cells, the cytotoxicity against 
HER2 kinase addicted cancer cells and EGFR kinase addicted cell lines of candidate 
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compounds were evaluated. Three types of cell lines including HER2 activated gastric 
cancer cell line (NCI-N87), HER2 activated breast cancer cell line (SK-BR3), and HER2 
gene transfected BaF3 cells were used to investigate the HER2 kinase inhibitory activity 
of the compound in cells. For the evaluation of EGFR inhibitory effect in cells, EGFR 
activated A431 cells, keratinocyte cells, and EGFR gene transected BaF3 cells were used.  
Through the cytotoxicity assays screening, three types of hit compounds were identified 
and further derivatized to prepare another hundreds of compounds in total which showed 
the cytotoxicity in HER2 activated cells, while sparing to EGFR addicted cells. 
In the next step, the modification of the candidate compound to improve the DMPK 
profile were conducted. Regarding the route of administration of the medicine, an oral 
agent is useful for the patients from an aspect of quality of life, compared to an 
intravenous injection agent. To develop the orally available compound, mouse exposure 
test were conducted for the candidates compound, and the candidates which showed the 
preferable mouse exposure by oral administration were selected. Stability of the 
compounds in blood is also considered. 
Cytochrome P450 (CYP) enzymes are monooxygenases which is responsible for drug 
metabolism, since anti-cancer drugs are often used concomitantly with other agents, if 
the drug which may affect CYPs, the combination of the drugs results in the narrow 
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therapeutic windows. Therefore, it is necessary to screen potential reversible and 
irreversible CYP inhibition in early drug research and development process. The 
compounds were further modified to consider the interaction with CYPs  Also, given 
that drug-drug interactions(DDI) in clinical setting results from the inhibition or 
induction of drug metabolizing enzymes, the inhibitory activity of candidate compounds 
for major eight CYP isoforms including CYP3A was investigated using human liver 
microsomes. In addition, the time-dependent inhibition potential of TAS0728 towards 
four CYP isoforms was examined by determining the apparent inactivation rate constant 
in human liver microsomes. Through the CYP assay screening, the candidate 
compounds that show no effect for the CYPs were selected to avoid the risk about DDI 
in human trials. 
 As the next screening, the compounds were further optimized to improve the metabolic 
stability in mouse and human. The candidate compounds were incubated under the 
presence of human and mouse microsome, and reminding compound was measured. As 
a result, the compound that has preferable metabolic stability were selected.  
Moreover, in vivo efficacy of the candidates were examined in mice xenograft tumor 
model bearing HER2 activated gastric cancer tumor, NCI-N87. As the results, the 
candidate compounds which have potential to induce the tumor shrinkage associated 
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HER2 kinase inhibition in tumor and no evident toxicity such as body weight loss were 
selected. 
Further evaluation to develop the candidate compounds as a clinical development 
candidate were performed. To find the optimal doses to identify the toxicological profile 
and potential toxicological risks of the compounds in the subsequent toxicity screening 
study, several compounds were administered at estimated moribund dose in rat.    
  Based on the preliminary toxicological screening study results, chemical properties 
such as solubility and stability, and the DMPK profiles, TAS0728 was selected as a 
candidate compound for the clinical development.   
 Finally, toxicity screening study of the compound in rat was conducted and revealed 
that the critical toxicological risks such as cardiovascular toxicity was not observed. 
 
1.4 Study aims and structure of this dissertation 
Although HER2 targeting therapies are used to the HER2-positive breast and gastric 
cancer, the medical need still exists for the other cancer types, or refractory population to 
the available therapies in breast and gastric cancer. To meet the medical need for the 
HER2 activated tumor, I set the target profile of next generation HER2 inhibitor, as 
“Highly selective, covalent-binding HER2 inhibitor”. To elucidate whether an identified 
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compound from TAIHO compound library meets the concept, the research about the 
characterization of antitumor profile and the molecular mechanism of the compound was 
conducted, based on the specific objectives of the study in this dissertation are as follows: 
1; Elucidation of antitumor profile and the antitumor mechanism of TAS0728, a 
new compound identified TAIHO pharmaceutical co. ltd. 
2; Validation of my hypothesis using the new compound, TAS0728 
Based on the specific objectives, a number of studies were conducted. Obtained data 
and associated discussion were described in the next three chapters.  
The structure of the dissertation was shown in Figure 1-5. In Chapter 1, a general 
introduction of HER2, cancer relevance of HER2, current status of HER2-targeting 
therapies and screening flow to identify the new compound were reviewed.  In chapter 
2, binding mode, pharmacodynamics, anti-tumor effect of identified compound, TAS0728, 
were described. In chapter 3, kinase selectivity and potential off-targets of TAS0728 were 
analyzed. In chapter 4, antitumor effect of the HER2 inhibitor in resistant models to 
conventional anti-HER2 therapies were investigated. Finally, in chapter 5, a general 
conclusion from the present work and the future perspective were summarized. 
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Table 1-1 Prevalence of HER2 gene abnormalities in various cancers 
Frequency of HER2 gene abnormality was summarized. Data from references [12] and 
[10]    
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Table 1-2. Conventional HER2 TKIs’ dose limiting toxicity (DLT) in human study. Data 
from references [31] 
 
 
 
 
 
 
 
 
 
 
 
Selectivity Major side-effect
Lapatinib
Non-selective
(inhibits EGFR) Grade3 diarrhea (DLT)
Neratinib
Non-selective
(inhibits EGFR) Grade3 diarrhea (DLT)
Afatinib
Non-selective
(inhibits EGFR) Grade3 diarrhea (DLT)
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A) 
 
B) 
 
Figure 1-1 A) Structure of ERBB family kinase. EGFR and HER3 assume a tethered 
structure in the absence of ligand. Ligand binding to the receptor promotes to open the 
conformation to allow to interact with other receptors. HER3 does not have functional 
kinase domain. Unlike other ERBB family kinases, HER2 is always in an open 
conformation that allows dimerization. The extracellular domain of HER2 consists of four 
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domains (I-IV). Domain II involves receptor-receptor interaction for the dimerization. 
The ERBB2-directed antibodies trastuzumab and pertuzumab bind domains IV and II, 
respectively.B) Activation of HER2-HER3 signaling pathway. Heterodimer formation of 
HER2 and HER3. Downstream pathway of HER2 is dependent on heterodimerzation of 
the HER2 and HER3. Phosphorylation of HER2 kinase domains initiates a downstream 
signaling cascade results in cell growth, proliferation, invasion metastasis, and 
angiogenesis in cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
26 
 
  
Figure 1-2 Clinical responses of lapatinib as a single agent treatment and molecular 
mechanism of HER3 reactivation. Inhibiton of HER2 kinase by Laptinib result in AKT-
associated feedback upregulation of HER3.  
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 Figure 1-3 Structural similarity between EGFR and HER2. In ATP-pocket of HER2 
kinase, Ser783 is a HER2 specific amino acid which is equivalent to Cys 775 in EGFR.  
 
 
 
 
 
Cys805
HER2: Ser783 EGFR: Cys 775
HER2 specific
amino acid
ATP-pocket
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Figure 1-4. Screening flow of a novel HER2 selective inhibitor. Screening flow consists 
of “Hit screening” to identify an initial hit, “Hit to lead” to optimize the hit compounds, 
“Lead optimization” for further optimization of the compound.  
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 Figure 1-5 Structure of this dissertation 
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Chapter 2: Mode of action of TAS0728 
2.1 Introduction 
To date, several small molecule HER2 inhibitors have been developed. The first 
generation of HER2 inhibitors such as lapatinib bind to HER2 in an ATP-competitive 
manner.  However, as described in chapter 1, the response rate to lapatinib as the 
monotherapy in chemotherapy-refractory HER2-positive breast cancer showed less than 
10%. A previous study that reported the resiliency of the HER2/HER3 signaling 
pathway is clue to explain the poor clinical outcomes associated with lapatinib therapy 
[23]. Indeed, the buffering activity of the HER2/HER3 pathway was shown to be related 
to the HER3 reactivation mechanism, and full inactivation of HER2 with high-dose 
lapatinib regimen may vanquish the negative feedback reactivation of HER3. Consistent 
with this concept, extremely high doses of lapatinib as a monotherapy with 5-day 
intermittent dosing elicited dramatic clinical responses, although concomitant treatment 
of a CYP inhibitor was required to achieve and keep high plasma concentrations [24]. 
Therefore, robust inhibition of HER2 signal may result in dramatic responses in HER2-
addicted tumors. 
I aimed to identify a covalent-binding, selective inhibitor of HER2 as a next 
generation HER2 kinase inhibitor, and tried to screen lead compounds to develop a 
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covalent-binding, selective HER2 inhibitor. Accordingly, TAS0728 was identified as a 
candidate to be developed. To develop the TAS0728 as an anti-tumor medicine, the 
clarification of antitumor profile and the antitumor mechanism is required. 
In this chapter, I aimed toclarify the antitumor profile and the antitumor mechanism 
of TAS0728 though analyzing binding mode, pharmacodynamics, of TAS0728. 
Furthermore, in vivo efficacy studies were conducted to clarify antitumor profile of 
TAS0728 in vivo mice models mimicking human cancers. 
 
2.2 Material and methods 
Compounds and Antibodies 
TAS0728 were synthesized at Tsukuba Research Institute, Taiho Pharmaceutical Co., 
Ltd.. Lapatinib was purchased from LC Laboratories (Woburn, MA, USA). Afatinib was 
purchased from Selleck Chemicals (Houston, TX, USA). Reagents were dissolved in 
dimethyl sulfoxide (DMSO) for in vitro assays. For in vivo experiments, TAS0728 was 
dissolved in 0.1 N HCl solution or 0.1 N HCl with 0.5% Hydroxypropyl Methyl Cellulose 
(HPMC). Lapatinib and afatinib were suspended in vehicle, as described in previous 
reports [29, 32]. 
The following antibodies were purchased from Cell Signaling Technology Japan, K.K. 
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(Tokyo, Japan) and used for Western blotting: anti-phospho HER2 (Tyr1196; #6942), 
anti-HER2 (#2165), anti-phospho-HER3 (Tyr1289; #4791), anti-HER3 (#12708), anti-
phospho-p44/42 MAPK; Thr202/Tyr204; #4370), anti-p44/42 MAPK (#4695), anti-
phospho-AKT (Ser473; #4060), anti-AKT (#4685), anti-BIM (#2933), anti-cleaved 
PARP; #9541), anti-β-actin (#8457), anti-phospho-EGFR (Tyr1068; #2234), anti-EGFR 
(#2232), and anti-rabbit IgG (#7074). 
 
Covalent binding analysis 
The recombinant human HER2 cytoplasmic domain (Carna Biosiences, Kobe, Japan) (1 
µmol/L) was incubated with TAS0728 (50 µmol/L) at room temperature for 24 hours. 
After reduction and alkylation with dithiothreitol (DTT; Thermo Fisher Scientific K.K., 
Tokyo, Japan) and iodoacetamide (Thermo Fisher Scientific K.K.), the protein was 
digested at 37°C with trypsin/Lys-C (Promega, Madison, WI, USA) in digestion buffer 
with 1mol/L ammonium bicarbonate solution (pH 8.0). The mass spectrum of the 
compound/kinase complex was detected with a quadrupole time-of-flight mass 
spectrometer (Xevo G2-S QTof; Waters Corporation, Tokyo, Japan) coupled with an 
ultrahigh performance liquid chromatography system (ACQUITY UPLC I-Class; Waters 
Corporation) in positive electrospray ionization mode. This system was equipped with an 
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Aeris WIDEPORE 3.6µ XB-C18 150 × 2.1 mm column (Phenomenex, Torrence, CA, 
USA) and was operated at a flow rate of 0.3 mL/min and a column temperature of 50°C. 
The gradient of mobile phase A (water, 0.1% formic acid [v/v]) and B (acetonitrile, 0.1% 
formic acid [v/v]) was performed as follows: 2% B for 3 min, 2% to 50% B for 37 min, 
50% to 90% B for 10 min. The data were acquired in MSE mode with collision energy of 
4 eV for low-energy scans and ramped from 15 to 40 eV for high-energy scans. Further 
data analysis was performed using BioPharmaLynx1.3.3 software (Waters Corporation).  
 
Dilution assay to test irreversible binding of compounds 
The irreversibility of the kinase inhibition of compounds was analyzed by dilution with 
ATP solution following pre-incubation of recombinant human HER2 with compounds. 
The recombinant human HER2 (Carna Biosciences) was pre-incubated with 5 μmol/L 
TAS0728, or 5 μmol/L lapatinib in assay buffer consisting of 13.5 mmol/L Tris-HCl(pH 
7.5), 0.009% Tween20, and 2 mmol/L DTT at 25°C for 30 min. The compounds/kinase 
complexes were then diluted 125-fold with the assay buffer containing 400 µmol/L ATP, 
10 mmol/L MnCl2, and 0.5 µmol/L FL-peptide 22. The recovery of enzyme activity from 
a preformed enzyme-inhibitor complex was measured using LabChip EZ Reader Mobility 
Shift assays (PerkinElmer, MA, USA).  
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 In vitro pharmacodynamics studies 
In the pharmacodynamics time-course experiment, SK-BR-3 cells were seeded in 100-
mm dishes and cultured overnight. Compounds were added and incubated for 3 or 48 
hours. The cells were harvested to perform Western blot analysis. 
In the evaluation of TAS0728’s inhibitory activity for phosphorylation of HER2 wild 
type and HER2 C805S (Cysteine to serine substitution) in cells, HEK293 cells transiently 
transfected with HER2 wild type or HER2 C805S gene on the PiggyBac vector using 
lipofectamin 2000 were seeded in dishes and cultured overnight. TAS0728 were added 
and incubated for 3 hours. The cells were harvested to perform Western blot analysis. 
 
Western blot analysis 
Cells were lysed in cell protein extraction buffer containing Cell Extraction Buffer (Life 
Technologies Corporation, Tokyo, Japan), cOmplete Mini Protease Inhibitor Cocktail 
(Roche Diagnostics K.K., Tokyo, Japan), and PhosSTOP Phosphatase Inhibitor Cocktail 
(Roche Diagnostics). Proteins were separated by SDS-PAGE and transferred to 
polyvinylidene difluoride (PVDF) membranes using a Trans-Blots Turbo RTA Midi 
PVDF Transfer Kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Membranes were 
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blocked with Blocking One-P blocking reagent (Nacalai Tesque, Inc., Kyoto, Japan) and 
probed with appropriate primary antibodies. The membranes were then incubated with 
anti-rabbit IgG antibody. The proteins were detected using luminol-based enhanced 
chemiluminescence with SuperSignal West Dura (Thermo Fisher Scientific K.K.) or 
SuperSignal West Femto (Thermo Fisher Scientific K.K.). Luminescent images were 
captured with an ImageQuant LAS 4010 or Amersham Imager 600 QC (GE healthcare 
Japan, Tokyo, Japan). 
 
Analysis of pharmacokinetics and in vivo pharmacodynamics  
All animal experiments were conducted with approval of the Institutional Animal Care 
and Use Committee of Taiho Pharmaceutical Co., Ltd. and carried out according to the 
guidelines for animal experiments of Taiho Pharmaceutical Co., Ltd. Nude mice 
(BALB/cAJcl-nu/nu) were purchased from CLEA Japan, Inc (Tokyo, Japan). For 
pharmacokinetics, TAS0728 was administered orally to male nude mice. Plasma samples 
were collected according to the sampling schedule (pre-dose, 0.25, 0.5, 1, 2, 4, 6, and 24 
hours) after dosing. Plasma samples were analyzed using liquid chromatography with 
tandem mass spectrometry (LC-MS/MS). 
For in vivo pharmacodynamics evaluation, suspensions of NCI-N87 cells were 
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implanted subcutaneously into the side flanks of 6-week-old male nude mice. Mice were 
randomized into the control and treatment groups (n = 3). Tumors were collected from 
animals, snap frozen in liquid nitrogen, and stored in a deep freezer for 
pharmacodynamics analysis. Tumor tissues were lysed in lysis buffer containing Sample 
Diluent Concentrate 2 (R&D Systems, Inc., MN, USA), cOmplete Mini Protease Inhibitor 
Cocktail (Roche Diagnostics), and PhosSTOP Phosphatase Inhibitor Cocktail (Roche 
Diagnostics), and processed for Western blot analysis as described above. 
 
In vivo efficacy studies 
Nude mice (BALB/cAJcl-nu/nu) were purchased from CLEA Japan, Inc. Severe 
combined immune deficient (SCID) mice (CB17/Icr-Prkdcscid/CrlCrlj) were purchased 
from Charles River, Japan, Inc. (Kanagawa, Japan). Suspensions of cells were implanted 
subcutaneously into the side flanks of 6-week-old nude mice. The tumor volume (TV, 
mm3) was calculated as the length (mm) × width (mm)2 / 2. During the treatment period, 
TV and body weight (BW) were measured twice per week. When the TVfinal was smaller 
than the TVinitial in the treatment group, tumor regression was judged to have occurred. 
As an indicator of changes in BW during the dosing period, the BW change (BWC; %) 
was calculated as 100 – ([BW on each measurement day] – [BWinitial]) / (BWinitial), where 
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BWinitial is the body weight on the allocation day. Dunnett tests or Aspin-welch t-test were 
used as a statistical method to compare the tumor volume data in the drug-treated and 
control groups. 
To establish a peritoneal dissemination model with HER2-addicted cancer cells, NCI-
N87-luc cells stably expressing the luciferase gene were established by transfection with 
the luciferase expression vector using PiggyBac vector system. The cells were cloned 
using Puromycine and authenticated by short tandem repeat profiling. The expression of 
luciferase activity was confirmed using a Dual-Glo Luciferase Assay System (Promega 
Corporation). Cell suspensions (4×107 cells/mL) in phosphate-buffered saline were 
inoculated intraperitoneally into SCID mice, as previously described[33]. Engraftment of 
tumors in mice was confirmed using bioluminescence values that were evaluated with an 
IVIS Lumina II Imaging System (Perkin Elmer Inc.) and randomized into each treatment 
group. Compounds were administered once daily. The increased life span was calculated 
using the median survival time (MST) in each treatment group. The mice were euthanized 
by isoflurane inhalation upon becoming moribund. The survival times of the drug 
treatment and control groups were compared using a log-rank test. Differences with P 
values of less than 0.05 were considered statistically significant. 
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2.3 Results  
TAS0728 is a covalent-binding inhibitor of HER2 kinase 
The identified new compound, TAS0728 is defined as a small molecule inhibitor, and the 
molecular weight was 504.58. TAS0728 is a pyrazolopyrimidine carboxamide analog 
with an acrylamide group which has a potential to form a covalent bond with the cysteine 
residue in the kinase domain of human HER2. The chemical structure is shown in Figure 
2-1. The IC50 value of TAS0728 against recombinant human HER2 enzyme, was 36 ± 3 
nmol/L.  
MS analysis revealed that TAS0728 covalently modified the cysteine residue at 
position 805 of recombinant human HER2 protein, (Figure. 2-2 A). Consistently, Amino 
acid substitution in cysteine residue at position 805 of HER2, which does not affect HER2 
kinase activity[34], resulted in the resistance to TAS0728 in cells. (Figure 2-2 B).  
To characterize covalent binding of TAS0728 to HER2, time-course of inhibitory 
activity of TAS0728 was evaluated in a high-concentration ATP reaction mixture after an 
enzyme-inhibitor complex was formed (Figure 2-3A). The reversible HER2 inhibitor 
lapatinib was used as a reference [35]. The lapatinib/HER2 complex showed the recovery 
of kinase activity after dilution with ATP, suggesting the dissociation of lapatinib from 
HER2 protein. In contrast, TAS0728 was not affected for 200 minutes after adding high-
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concentration of ATP, indicating that the inhibitory activity of TAS0728 was not sensitive 
to ATP concentration once TAS0728 bound to HER2 (Figure 2-3 A). The projected 
binding mode are described in figure 2-3 B. 
Taken together, these findings suggested that TAS0728 formed a covalent bond with 
HER2 and irreversibly inhibited the kinase activity of HER2. 
 
In vitro Pharmacodynamics (PD) and cytotoxicity of TAS0728 
In order to investigate the effects of TAS0728 on the phosphorylation of HER2 in cells, 
HER2-overexpressing SK-BR-3 cells was treated with TAS0728 for 3 hours. At 
concentrations ranging from 30 to 1000 nmol/L, TAS0728 strongly inhibited the 
phosphorylation of HER2 in SK-BR-3 cells. Consistently, TAS0728 exerted the 
cytotoxicity in SK-BR-3 cells at concentrations ranging from 30 to 1000 nmol/L. 
TAS0728 inhibited phosphorylation of HER2 and cell growth in a dose dependent manner 
(Figure 2-4). These results suggests that TAS728 target engagement and anti-proliferative 
effect were correlated. 
 
TAS0728 caused sustained inhibition of HER2/HER3 and downstream AKT/ERK 
pathways in cancer cells 
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In a previous research, the feedback reactivation of the downstream pathway of HER2 
signaling was observed during lapatinib exposure in HER2-amplified breast cancer cells 
(15). To compare the time-dependent pharmacodynamic effects of TAS0728 and 
lapatinib in SK-BR-3 cells, the cells were treated with TAS0728 or lapatinib for 3 and 48 
hours at concentrations ranging from 30 to 300 nmol/L. Western blotting analysis was 
performed to investigate the inhibitory effects of compounds on the phosphorylation of 
HER2, HER3, AKT, ERK. Although lapatinib initially inhibited HER2 signaling after 3 
hours of exposure, reactivation of HER2 and downstream molecules, including HER3, 
AKT, and ERK, was observed at 48 hours (Figure 2-5). In contrast, TAS0728 showed 
sustained inhibition of HER2, HER3, AKT, and ERK phosphorylation at concentrations 
ranging from 100 to 300 nmol/L during the 48-hour incubation. 
  
Sustained inhibition of AKT/ERK pathway results in BIM-induced apoptosis 
The expression of BIM (a key effector of apoptosis,[36]) and cleaved PARP (a marker of 
apoptosis) was examined. BIM and cleaved PARP were markedly increased after 
treatment of SK-BR-3 cells with TAS0728 for 48 hours at concentrations ranging from 
30 to 300 nmol/L, although these changes were not observed in the lapatinib group. These 
results suggested that TAS0728 had superior sustained inhibitory activity toward HER2 
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and downstream factors compared with lapatinib and that these effects were associated 
with apoptosis induction of cancer cells.  
 
Pharmacokinetics and pharmacodynamics of TAS0728 
To clarify the molecular mechanism of antitumor effect of TAS0728 in vivo, 
pharmacokinetics and pharmacodynamics were evaluated in mice. In a pharmacokinetics 
study in male nude mice, the plasma concentration-time profiles on day 14 were 
determined after daily oral administration of TAS0728 at doses of 7.5, 15, 30, and 60 
mg/kg/day for 14 days. The plasma concentration at the doses reached the maximum 
observed plasma concentration (Cmax) less than 0.5 hour after dosing. For the dose range 
tested (7.5–60 mg/kg/day), TAS00728 concentration in plasmaat each time point 
increased in a dose-dependent manner. TAS0728 was rapidly eliminated within 24 hour, 
and the biological half-life of TAS0728 at 60 mg/kg in mice was less than 1 hour. At 6 
hour after administration, most TAS0728 was eliminated from plasma (Fig.2-7).    
Pharmacodynamics analysis at 60 mg/kg/day of TAS0728 with the single dose 
revealed that phosphorylation of HER2, HER3, AKT, and ERK was decreased compared 
with that in the control group at 0.5, 1, 4, and 8 hour after administration. The inhibition 
was continued up to 8 hour after administration and recovered to around 75% at 12 hour 
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(Fig. 2-8). These analyses revealed that sustained target inhibition was observed after 
elimination of TAS0728 in the plasma of mice.  
 
Antitumor activity and survival benefit of TAS0728 in mouse xenograft models 
I determined the in vivo efficacy of TAS0728 in a NCI-N87 HER2-amplified human 
gastric cancer mouse model. The animals were orally administered TAS0728 at different 
doses. Dose-dependent antitumor effect of TAS0728 was observed(Fig. 2-9A). Further 
more, significant tumor regression was observed in mice treated with 60 mg/kg/day. 
Afatinib (20 mg/kg/day) also showed antitumor effects in this model, as described 
previously (21). all doses were well tolerated in all mice because no significant loss in 
body weight was observed (Fig.2-10).I next evaluated the in vivo efficacy of TAS0728 in 
another model bearing HER2-amplified breast tumors. In this model, administration of 
TAS0728 at 30 or 60 mg/kg/day resulted in tumor regression. In contrast, tumor shrinkage 
was not observed in the lapatinib-treated group (Fig. 2-9 B).  
To evaluate the effects of TAS0728 on survival and the tolerability of long-term daily 
dosing, I established an NCI-N87-luc peritoneal dissemination model to compared the 
efficacy and tolerability of once-daily oral dosing of TAS0728, afatinib, and lapatinib. 
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The dosing was started on day 7 after implantation. The median survival times (MSTs) 
were 60 days in the untreated control group and 77 days in lapatinib-treated mice. In 
contrast, no mice died in the afatinib- or TAS0728-treated groups during the 120-day 
experimental period (Fig. 2-11). In this model, any significant evident toxicity including 
diarrhea and a body weight loss were not observed by the long-term dosing of TAS0728. 
 
2.4 Discussion 
TAS0728 was found to be a covalent-binding inhibitor of HER2 kinase. TAS0728 
covalently bound to Cys805 in HER2 and inhibited kinase activity. In addition to the 
kinase domain binding moiety of TAS0728, covalent binding moiety of TAS728 has a 
great influence for the HER2 inhibitory effect. Since lapatinib inhibits HER2 kinase 
activity via ATP competitive manner, the inhibitory activity is attenuated by adding 
ATP[35]. Unlike lapatinib, the inhibitory activity of TAS0728 for HER2 kinase was not 
affected by the presence of high concentration of ATP after binding to HER2 peptide, 
which is a particular characteristic of covalent-binding TKIs. To achieve durable 
inhibition of HER2 kinase activity in cancer cells, irreversible inhibition would be an 
advantage of TKIs. A previous study suggested that the HER2/HER3 signal in HER2-
amplified cancer cells is resilient; thus, higher doses of lapatinib, which are required to 
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block HER2/HER3 signaling, may result in dramatic antitumor responses in HER2-
positive cancer cells [24]. In our study, although lapatinib initially inhibited the 
phosphorylation of HER2 and the downstream pathway, reactivation of these molecules 
was observed after 48 hours of continuous exposure, consistent with previous reports. 
The mechanism of the negative feedback activation is considered dependent on the 
enhanced expression of HER3 protein as shown figure2-5. The HER3 protein can be 
reactivated by HER2. In the previous report, FoxO3A, a downstream target transcription 
factor of AKT, was identified as regulator of HER3 expression [37]. They have also 
reported that knockdown of FoxO3a, downregulated levels of both basal and lapatinib-
induced increase in HER3 expression. In contrast, overexpression of FoxO3Aby transient 
transfection increased HER3 mRNA level. Therefore, HER2-AKT pathway inhibition by 
lapainib is considered to induce FoxO3 activation, followed by induction of HER3 
expression.  The induced HER3 by lapatinib treatment is phosphorylated by remained 
HER2 activity, and HER2-HER3 reactivation is occurred. The expected mechanism of 
HER2-HER3 feedback reactivation were proposed as in Figure 2-5 B. It is considered 
that full inactivation of HER2 kinase activity may be required to overcome the signal 
reactivation.  Lapatinib at recommended dose in clinical setting may not achieve the 
required concentration to overcome HER2-HER3 reactivation, since the dose cannot be 
45 
 
escalated due to the side-effect.  
..In contrast, TAS0728 induced durable inhibition of the phosphorylation of HER2 and 
downstream molecules after 48 hours of treatment. Consistent with these findings, 
increased BIM protein and cleaved PARP were observed in the TAS0728-treated group, 
suggesting that apoptosis was induced in these cancer cells. Moreover, in vivo, TAS0728 
induced tumor shrinkage in xenograft models, accompanied by increased BIM expression 
and cleaved PARP levels in the tumor tissues. As shown in figure 2-9B, lapatinib did not 
induce tumor regression in mice. TAS0728 irreversibly inhibits HER2 while lapatinib 
reversibly inhibits HER2. Threfore, the different pharmacological activities of TAS0728 
and lapatinib are presumably due to differences in the binding modes of the two 
compounds. Thus, TAS0728 has the potential to exceed the clinical activity of lapatinib 
as a single agent. Consistently, the cell panel assay revealed that TAS0728 showed the 
antitumor activity for only HER2 activated cancer cell lines originated from breast, gastric, 
and lung cancer, while not for non-HER2 activated cancer cell lines. Collectively, these 
results indicated that TAS0728 exerted the antitumor activity through the HER2 kinase 
inhibition. 
In addition to HER2-HER3 pathway, another negative feedback system have been 
reported in the RAS/ERK pathway which is one of the most commonly affected signaling 
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pathways in human cancer[38]. Targeting the ERK pathway in various cancer types and 
can result in initial responses. However, a form of intrinsic resistance occurs frequently, 
resulting in recurrence or progression, due to the negative feedback system. In the study, 
the combination treatment with SHP2 inhibition and MEK inhibition was proposed to 
overcome the negative feedback in cancer cells. To improve the current therapy against 
cancer, understanding the negative feedback system as a resistant mechanism is expected 
to become more important.  
In conclusion, TAS0728 is a covalent-binding inhibitor of HER2 kinase. TAS0728 
exerted the anti-proliferative activity through the inhibition of phosphorylation of HER2 
in HER2-activated cancer cells. The robust and sustained inhibition of HER2 signaling 
pathway results in the apoptosis induction by overcoming the negative feedback system 
of the pathway in the cancer cells 
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Figure 2-1. Chemical structure of TAS0728. Molecular weight of TAS0728 is 504.58. 
IC50 value against HER2 recombinant was 36 ± 3 nmol/L. 
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Figure 2-2. A, MS spectrum for protease-digested peptide with TAS0728. MSE spectrum 
for protease-digested recombinant human HER2 peptide 
(LLGICLTSTVQLVTQLMPYGCLLDHVR) bound to TAS0728. TAS0728-HER2 
complex was digested with protease and analyzed by LC-MSE peptide profiling. 
Fragment ions of HER2 peptide containing C805 were shifted in a manner corresponding 
to the molecular mass of TAS0728, suggesting TAS0728 covalently bound to HER2 at 
C805. B, Inhibitory activity of TAS0728 for phosphorylation of HER2 wild type and 
HER2 C805S in cells. HEK293 cells expressing HER2 wild type and HER2 C805S were 
treated TAS0728 for 3 hours and harvested. Phosphorylation of HER2-Tyr1196 in the cell 
extract was determined using Western blot analysis. 
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Figure 2-3. A, Dissociation of TAS0728 from recombinant HER2 protein. Time course 
of TAS0728 inhibition on recombinant HER2. The reaction was initiated by diluting a 
preformed enzyme-inhibitor complex into reaction buffer. The recovery of activity 
reflected the dissociation of inhibitor to generate the active enzyme. The results are 
presented as the mean kinase activity of duplicate data. B, Projected binding mode of 
TAS0728 by docking-study.  
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Figure 2-4 In vitro pharmacodynamics and cytotoxicity of TAS0728.,SK-BR3 cells were 
treated with TAS0728 at the indicated concentrations, and A, phosphorylated HER2 was 
detected after 3 hours, and B, viable cells were measured after 72 hours of treatment and 
plotted relative to vehicle control. 
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Figure 2-5. A) Inhibition of HER2 signaling by TAS0728 in HER2 overexpressing 
SKBR3. The cells were cultured with TAS0728 or lapatinib and harvested 3 or 48 h after 
treatment. Phosphorylation of HER2-Tyr1196, HER3-Tyr1289, AKT-Ser473, and 
ERK1/2-Thr202/Tyr204 were determined using Western blot analysis..B) Proposed 
mechanism of HER2-HER3-AKT feedback reactivation by lapatinib’s HER2 inhibition. 
HER2-AKT pathway inhibition by lapainib results in FoxO3 activation, followed by 
induction of HER3 expression.  
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Figure 2-6 A) Induction of BIM isoforms and cleaved PARP by TAS0728 in HER2 
overexpressing SKBR3 cells. B) Proposed mechanism of apoptosis induction associated 
with BIM stabilization by TAS0728. The cells were cultured with TAS0728 or lapatinib 
and harvested 3 or 48 h after treatment. Expression of BIM and cleaved PARP were 
determined using Western blot analysis. 
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Figure 2-7 Phamacokinetics of TAS0728 in mice. Plasma concentration profiles over time 
on day 14 in nude mice. The control group was administered vehicle instead of TAS0728. 
Data are presented as mean plasma concentration ± SDs   
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Figure 2-8 Time-course of the in vivo pharmacodynamics activity of TAS0728 on HER2 
and downstream molecules in xenograft tumors. Mice bearing NCI-N87 xenografts were 
administered TAS0728 at 60 mg/kg. At 0.5, 1, 4, 8, 12, and 24 hours after the 
administration of TAS0728, xenograft tumors were collected (n= 3 per group). 
Phosphorylation of HER2-Tyr1196, HER3-Tyr1289, AKT-Ser473, and ERK1/2-
Thr202/Tyr204 and expression of BIM isoforms and cleaved PARP were determined 
using Western blot analysis. 
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 Figure 2-9 in vivo antitumor activity of once-daily oral administration of TAS0728 in 
mouse xenograft models. A, Inhibition of tumor growth in mice bearing NCI-N87 
xenografts treated with TAS0728 or afatinib for 14 days (n= 6 per group). *, P<0.01 
compared with the control group in the TAS0728 by Dunnet test or afatinib group by 
Aspin-Welch t test. B, Inhibition of tumor growth in mice bearing BT-474 xenografts 
treated with TAS0728 or lapatinib for 21 days. (n=5-6 per group). *,P<0.001 compared 
with the control group in the TAS0728 by Dunnett test, or lapatinib group by Aspin-Welch 
t test. 
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Figure 2-10 Body weight changes in mice bearing NCI-N87 xenografts treated with 
TAS0728 or afatinib for 14 days (n = 6 per group).  
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Figure 2-11 Kaplan-Meier survival curve of CB17/Icr-Prkdcscid/CrlCrlj mice 
intraperitoneally inoculated with NCI-N87-luc cells. Seven days after implantation, mice 
were grouped according to photon values measured by an IVIS Imaging System followed 
by once-daily administration of TAS0728, lapatinib, or afatinib (n = 7 per group). 
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Chapter 3: Selectivity and potential off-targets of TAS0728 
3.1 Introduction 
Various covalent-binding irreversible inhibitors of HER2 have been developed and have 
been shown to exhibit robust and sustained target engagement in preclinical studies (21, 
22). In 2017, neratinib was approved to be used in the adjuvant setting for HER2-positive 
MBC. However, these reported HER2 inhibitory covalent binders are not selective for 
HER2 and instead act as pan-ERBB tyrosine kinase inhibitors (TKIs) that block the 
activity of ERBB family kinases, including EGFR. Although EGFR is also a well-
recognized drug target in cancer, inhibition of this kinase in normal tissues can result in 
dose-limiting gastrointestinal (GI) issues and rashes, particularly diarrhea to the level of 
grade 3 or 4 toxicity. This was clearly reported in the ExteNET trial of neratinib (20) and 
the LUX-BREAST 1/3 studies of afatinib (17, 18). Therefore, the high selectivity for 
HER2 inhibition excluding EGFR may allow for more effective dosing to overcome the 
resiliency of the HER2/HER3 pathway in HER2-activated cancers and improve the 
clinical response rates of conventional HER2 TKIs. However, identification of HER2-
selective covalent inhibitors is still challenging. 
In this chapter, I evaluated the kinase selectivity of TAS0728 with a kinome-wide 
biochemical panel, non-kinase binding assay, cellular assays, and apoptosis induction 
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assay. 
 
3.2 Material and methods 
The inhibitory activity of TAS0728 for 386 or 374 kinases was tested using Kinase Panel 
Assay at Reaction Biology Corporation (Malvern, PA, USA). The assays were conducted 
in duplicate mode at concentrations of 0.1, 1, and 10 μmol/L TAS0728. Reactions were 
carried out in the presence of 10 μmol/L ATP.  
 
IC50 determination of TAS0728 against recombinant kinases. 
The study was conducted using HotSpot 10-dose Kinase Profiling at Reaction Biology 
Corporation. TAS0728 was teste in 10-dose IC50 with 3-fold serial dilution starting at 1 
μM in singlet against 1 kinase at 10 μM ATP.  
 
Binding assay of TAS0728 for 68 non-kinase molecules  
The study was conducted using LeadProfilingScreen at Eurofins Pnalabs Taiwan, ltd 
(Taiwan), IC50 values were determined by a non-linear, least squares regression analysis 
using MathIQTM (ID Business Solutions Ltd., UK). Where inhibition constants (Ki) are 
presented, the Ki values were calculated using the equation of Cheng and Prusoff  
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using the observed IC50 of the compound, the concentration of radioligand employed in 
the assay, and the historical values for the KD of the ligand. 
 
Cell lines and cell culture 
SK-BR-3 cells were purchased from Dainippon Pharmaceutical Co., Ltd (Osaka, 
Japan). A-431, AU565, BT-474, Calu-3, and NCI-N87 cells were provided from 
American Type Culture Collection (Manassas, VA, USA). KPL-4 cells were provided 
by Dr. Junichi Kurebayashi at Kawasaki Medical School [39]. The series of MCF10A 
cell lines stably expressing HER2-mutant genes was provided by Dr. Motoki Takagi at 
Fukushima Medical University (Fukushima, Japan), which were established as 
previously described [40]. The primary human epidermal keratinocytes (NHEK-NEO) 
cells were purchased from Lonza Walkersville, Inc (MD, USA). 
Cell lines were cultured in McCoy’s 5A Medium(Thermo Fisher scientific, Japan) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; MP Biomedicals, LLC, 
Lot No.: MP12934 SK-BR-3 cells), Dulbecco’s modified Eagle’s medium (DMEM) with 
10% heat-inactivated FBS (BT-474 and A-431 cells), RPMI1640 medium supplemented 
with 10% heat-inactivated FBS (MP Biomedicals, LLC , MP12934,  AU565, NCI-N87 
cells, and NCI-N87-luc), DMEM supplemented with 5% heat-inactivated FBS (MP 
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Biomedicals, LLC , MP12934, KPL-4 cells), or Eagle’s minimum essential medium 
supplemented with 10% heat-inactivated FBS (MP Biomedicals, LLC , MP12934, Calu-
3 cells). NHEK-Neo cells were cultured by using a KGM-Gold Bullet Kit (Lonza 
Walkersville, Inc.). MCF10A cells were cultured in DMEM/Ham’s F-12 medium 
supplemented with 10 μg/mL insulin, 500 ng/mL hydrocortisone, 5 μmol/L forskolin, and 
5 % heat-inactivated horse serum (Thermo Fisher scientific Inc.). 
 
Cell proliferation assay 
Cells were seeded in 96-well plates and then incubated under 37.0°C and 5.0% of CO2 
concentration overnight. Medium containing a compound or DMSO control was added, 
and cells were then incubated for 72 hours. The cell population densities were then 
measured using CellTiter-Glo 2.0 Reagent (Promega Corporation). 
 
Apoptosis induction 
SK-BR-3 cells were treated with TAS0728 or afatinib for 3 days at concentration of 
1000, 333, 111, 37, 12, 4.1, 1.4, 0.46 and 0.15 nmol/L. NHEK-Neo pooled cells were 
treated with TAS0728 or afatinib for 3 days at concentration of 10000, 3300, 1100, 370, 
123, 41, 14, 4.6 and 1.5 nmol/L. For Caspase-Glo® 3/7 Assay, 100 μL of Caspase-Glo® 
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3/7 Reagent was added to an equal volume of culture medium containing cells in each 
well of the 96-well plate, after incubation at room temperature for approximately 30 
minutes. 100 μL of Caspase-Glo® 3/7 Reagent was added to an equal volume of culture 
medium containing cells in each well of the 96-well plate. After mixing on a shaker for 
5 minutes to induce cell lysis, the plate was let stand at room temperature for 30 minutes 
with protection from light to allow stabilization of the luminescence. Then the 
luminescence of each well was measured with an EnSpire® Multimode Plate Reader. 
The extent of apoptosis (luminescence in the Caspase-Glo® 3/7 Assay) at each test 
compound concentration was normalized for cell viability (luminescence in the 
CellTiter-Glo® 2.0 Assay) by using the following equation 
Normalized Caspase-Glo® 3/7 Assay signal = (luminescence in the Caspase-Glo® 3/7 
Assay – luminescence of wells without cells) / (luminescence in the CellTiter-Glo® 2.0 
Assay – luminescence of wells without cells) 
Induction of apoptosis was assessed by calculating the ratio of each test compound-
treated group of wells to the control group. Statistical analyses were performed using 
Dunnett’s test with SAS ver. 9.2 software with EXSUS ver. 8.0.0. P-values of less than 
0.05 were considered significant. 
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 3.3 Results  
TAS0728 exhibited high selectivity for HER2 kinase  
To investigate selectivity of TAS0728, enzyme assays of a panel of 386 or 374 kinases 
were conducted. TAS0728 at 0.1 μmol/L showed an inhibition rate of greater than 80% 
(≥ 80% inhibition of activity) for three of the 386 kinases tested (Fig. 3-1 A). In a panel 
of 374 kinases, 12 and 19 kinases were inhibited by more than 80% at 1 and 10 μmol/L, 
respectively (Fig. 3-1 B,C). IC50 values of TAS0728 against HER2 and EGFR 
recombinant which were used in the kinase panels were 13 nM and 65 nM, respectively. 
IC50 values of TAS0728 for HER2, EGFR, and other off-target kinases were listed in 
Table 3-1. Moreover, the LeadProfilingScreen containing 68 non-kinase molecules 
(Eurofins Panlabs, Taipei, Taiwan) revealed that TAS0728 at 10 μmol/L did not bind to 
the 68 targets. The list of non-kinase targets tested is shown in Table3-2. 
In order to investigate the effects of TAS0728 on the phosphorylation of HER2 in cells 
and the specificity excluding EGFR, HER2-overexpressing SK-BR-3 cells and EGFR-
overexpressing A-431 cells were treated with TAS0728 for 3 hours. At concentrations 
ranging from 30 to 1000 nmol/L, TAS0728 strongly inhibited the phosphorylation of 
HER2 in SK-BR-3 cells. On the other hand, phosphorylation of EGFR was only weakly 
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inhibited even at a concentration of 1000 nmol/L in A-431 cells (Fig. 3-2). In contrast, 
afatinib inhibited the phosphorylation of HER2 in SK-BR-3 cells at concentrations 
ranging from 100 to 300 nmol/L and inhibited the phosphorylation of EGFR in A-431 
cells at concentrations ranging from 10 to 300 nmol/L. These results suggested that 
TAS0728 had higher selectivity for HER2 than EGFR. 
In addition to amplification or overexpression of HER2, mutations in HER2, an 
alternative activation mechanism, have been reported in several cancers. To investigate 
the effects of TAS0728 on the phosphorylation of mutated HER2 in cells, MCF10A cells 
stably expressing wild-type HER2 protein or various HER2 mutants were treated with 
TAS0728. Phosphorylation of wild-type or mutant HER2 was examined in control and 
treated cells. The inhibitory effects of TAS0728 on the phosphorylation of various HER2 
mutants in the extracellular domain (G309A, S310F) and in kinase domain (R678Q, 
L755_T759 deletion, D769H, V777L, V842I, and R869C) was equivalent to that of wild-
type HER2 (Fig. 3-3). A slightly higher concentration was required to inhibit the 
phosphorylation of HER2 L755S and ex20insYVMA in the kinase domain, although this 
concentration was still lower than that required for inhibition of wild-type EGFR. These 
results suggested that TAS0728 had inhibitory effects on the phosphorylation of various 
HER2 mutants and on overexpressed wild-type HER2 at a concentration lower than that 
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for inhibition of wild-type EGFR(Figure 3-3). 
To examine the cell line selective cytotoxicity of TAS0728 for HER2-amplified and 
EGFR-activated cell lines, the drug concentration of 50% growth inhibition (GI50) values 
were determined for seven cancer cell lines, including HER2 gene-amplified cells, wild-
type EGFR gene-amplified cells, and primary normal human epidermal keratinocytes 
showing EGF-dependent cell growth (Table 3-3). TAS0728 potently inhibited the in vitro 
proliferation of five HER2-amplified cell lines, and the GI50 values were less than 10 
nmol/L. For KPL-4 cells, a HER2-amplified, PIK3CA-mutated breast cancer cell line, 
the GI50 value of TAS0728 was relatively higher than those of the other five HER2-
amplified cell lines. The GI50 values of TAS0728 for EGFR-amplified A-431 cells and 
EGFR-expressing normal keratinocytes (NHEKs) were more than 10-fold higher than 
those of HER2-amplified cell lines. In contrast, the GI50 values of afatinib were almost 
equivalent for both HER2-amplified cell lines and EGFR-activated cell lines, except in 
KPL-4 cells. These findings suggested that TAS0728 had potent inhibitory activities 
against cancer cell lines with HER2 amplification, but showed reduced activity in cells 
addicted to EGFR signals. 
  
Apoptosis induction 
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Apoptosis markers, caspase 3 and 7, are mediators of a common apoptosis pathway 
triggered by various stimuli[41]. To investigate apoptosis induction by TAS0728 in 
HER2 amplified cancer cells and normal human epidermal keratinocyte cells, SK-BR-3 
cells and NHEK-Neo pooled cells were treated with TAS0728 and induction levels of 
caspase 3/7 were examined. 
Induction of caspase 3/7 in SK-BR-3 cells by treatment with TAS0728 at 
concentrations from 37 to 1000 nmol/L was observed. In contrast, caspase 3/7 induction 
was not observed in normal human epidermal keratinocyte cells by TAS0728 at 
concentrations from 1.5 to 10,000 nmol/L. To obtain reference information, SK-BR-3 
cells and NHEK-Neo pooled cells treated with afatinib induction level of caspase 3/7 
were examined. Induction of caspase 3/7 in SK-BR-3 cells by treatment with afatinib 
was observed at concentrations from 37 to 1000 nmol/L. Induction of caspase 3/7 in 
NHEK-Neo pooled cells were also observed at concentrations from 3333 to 10,000 
nmol/L (Fig 3-4). These results suggested that TAS0728 had an apoptosis inducing 
ability for cancer cells.  
 
3.4 Discussion 
Diarrhea is a common side effect of EGFR TKIs. It is suggested that the mechanism of 
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diarrhea caused by EGFR TKIs is activation of basolateral membrane potassium (K+) 
channels and apical membrane chloride (Cl–) channels in intestinal epithelia [42]. The 
concept of avoiding EGFR-related toxicity may be supported by clinical data with 
osimertinib, which shows high specificity for EGFR T790M over wild-type EGFR; 
when using osimertinib, mild rash and diarrhea were reported in only a minority of 
patients[43]  
TAS0728 is a highly selective irreversible kinase inhibitor for HER2. Compared with 
afatinib, TAS0728 had higher specificity for HER2 than for EGFR, as demonstrated in 
the panel enzymatic assay, cellular pharmacodynamics assay, and cytotoxicity assay. 
Consistently, although frequent diarrhea was observed in afatinib treated mice, but not 
in TAS0728 treated group as shown in Figure 2-11  Cys775 in HER2 and Serine783 is 
the only residue difference as shown in figure 1-3. TAS0728’s structure may have the 
different steric hindrance against the amino acids in HER2 and EGFR.   
On the other hand, high kinase selectivity of TKI is not always a good thing. TAS0728 
may not be effective for heterogeneous tumors. Intratumoral HER2 heterogeneity is 
frequently observed in HER2 overexpressed gastric cancer[44]. The incidence of HER2 
heterogeneity evaluated by IHC is widely reported from 39.0 to 75.4%. The clinical 
significance of HER2 heterogeneity on trastuzumab efficacy have been reported. 
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Theoretically, the selective inhibition of HER2 is not effective heterogeneity of the tumor. 
Therefore, one of the challenges of TAS0728 for clinical studies is the selection of the 
right patients who will be sensitive for an HER2 selective inhibitor.    
In conclusion, TAS0728 is a highly selective inhibitor of HER2 kinase. The high 
selectivity of the compound allows the tumor selective apoptosis induction as well as 
tumor type selective anti-proliferative effect. Therefore, the high selectivity allows not 
only reduce the side-effect but also more effective, higher dosing in patients.  
 
 
 
 
 
 
 
70 
 
 Table 3-1 IC50 values of TAS0728 against kinases that showed at least 50% inhibition at 
0.1 μmol/L of TAS0728 in a panel of 374 kinases. The assays were conducted in duplicate 
mode in the presence of 10 μmol/L ATP.  
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Table 3-2 The list of 68 non-kinase targets tested in a panel of binding assays of 
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TAS0728  at 10 μmol/L. The panel assay was performed  using LeadProfilingScreen. 
(Eurofins Panlabs, Taipei, Taiwan) 
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Table 3-3 Drug concentration of 50% growth inhibition (GI50) values for cancer cell 
lines.aGenetic information was obtained from publishd article. bGI50: drug concentration 
causing 50% growth inhibition relative to the untreated control. 
 
 
 
 
 
 
 
 
 
Cell line Primary site of 
origin
Genetic alterationa GI50b (nmol/L)
TAS0728
(mean ± SDc)
Afatinib
(mean ± SD)
SK-BR-3 Breast HER2 amplified 5.0 ± 2.6 7.5 ± 1.4
AU565 Breast HER2 amplified 5.1 ± 0.5 4.6 ± 0.8
BT-474 Breast HER2 amplified 3.6 ± 0.5 3.0 ± 0.3
KPL-4 Breast HER2 amplified, 
PIK3CA mutated
31 ± 7 100 ± 29
NCI-N87 Gastric HER2 amplified 1.6 ± 0.3 1.0 ± 0.2
Calu-3 Lung HER2 amplified 6.9 ± 4.6 1.7 ± 1.2
A-431 Epidermis EGFR amplified 450 ± 220 14 ± 3
NHEK-Neo 
pooled
Keratinocyte - 620 ± 310 15 ± 10
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Figure 3-1. Kinase inhibition profile of TAS0728.The kinome-wide kinase selectivity 
profile of TAS0728 carried out against 374 protein kinases. Relative kinase activities of 
374 kinases were plotted as ranked by sensitivity to TAS0728 at 0.1 μmol/L (A), at 1 
μmol/L (B), and at 10 μmol/L (C). Kinases inhibited by more than 90% in response to 
TAS0728 treatment at each concentration are listed (D). The results for each kinase are 
presented as the mean kinase activity of duplicate data relative to the DMSO control 
sample. 
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Figure 3-2. Cellular kinase inhibition profile of TAS0728. Inhibition of HER2-Tyr1196 
phosphorylation in SK-BR-3 cells (A) or EGFR-Tyr1068 phosphorylation in A-431 cells 
(B) was determined by western blot analysis of lysates generated from 3-h treatment with 
TAS0728 or afatinib. 
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Figure 3-3 Inhibitory effects of TAS0728 on the phosphorylation of various HER2 
mutants in MCF10A cells. Inhibition of the phosphorylation of various HER2 mutants, 
wild-type HER2, and wild-type EGFR in MCF10A cells engineered to express HER2 or 
EGFR genes. Phosphorylation of HER2-Tyr1196 or EGFR-Tyr1068 was determined by 
western blot analysis of lysates generated from 3-h treatment with TAS0728. 
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Figure 3-4 Apoptosis induction by TAS0728 or afatinib at the indicated concentrations 
in cancer cells(A) or normal cells (B). Data are shown as mean ± SD (n = 3). *: p < 
0.001 in the drug treated group by Dunnett`s test as compared with the control group. $: 
p < 0.05 in the drug treated group by Dunnett`s test as compared with the control group. 
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Chapter 4:  TAS0728’s antitumor activity for the resistant models to the established 
anti-HER2 antibodies or ADC.  
 
4.1 Introduction 
HER2-targeting antibodies such as trastuzumab, pertuzumab and a HER2-directed 
antibody-drug conjugate (trastuzumab emtansine: T-DM1) are approved for the treatment 
of HER2 overexpressed breast cancer[15, 17]. Infirst line treatment for HER2 
overexpressed breast cancer patients, combination of trastuzumab, pertuzumab, and 
docetaxel is used [15]. Both trastuzumab and pertuzumab bind to HER2 receptor on the 
cancer cells and significant antitumor effect. Mode of action of trastuzumab’ antitumor 
activity has been considered to be dependent on not only HER2 signal inhibition but also 
antibody-dependent-cellular-cytotoxicity(ADCC) effect. Indeed, in trastuzumab sensitive 
BT474 tumor in FCγR KO nude mice, antitumor effect of trastuzumab was drastically 
reduced compared to that in BT474 tumor in FCγR intact nude mice [45].  Pertuzumab 
has been reported to bind to HER2 and to exert the antitumor activity by ADCC as well 
as blocking HER2-HER3 dimerization [46]. T-DM1, which is used in second line therapy 
in HER2 overexpressed breast cancer, displays the antitumor effect dependent on both 
microtubule assemble inhibition by DM1, payloads of T-DM1, and ADCC by HER2 
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antibody component. Although those treatments initially induced significant response in 
clinical settings, ultimately become refractory to the therapies. Therefore, an alternative 
effective therapy to overcome the resistant tumor is required. In addition, the molecular 
mechanism of development of the resistance to the Her2-targeting therapies in clinical 
setting are not elucidated, although several potential mechanisms has been proposed 
based on the pre-clinical studies. 
TAS0728 is a small molecule, irreversible kinase inhibitor selective for HER2. As 
described in Chapter 2 and 3, TAS0728 is an orally available and the mode of action of 
antitumor activity is based on the kinase signal inhibition, and assessment in human is 
ongoing. However, it is still unclear whether TAS0728 is effective for the refractory 
models for the therapy. In general, a compound with different mode of action may have 
the different resistant mechanisms, and be effective to overcome for resistant tumors. 
Therefore, I hypothesized that TAS0728 may have different mode of action from 
trastuzumab/pertuzumab or T-DM1 and aimed to evaluate whether TAS0728 is effective 
to resistant models to the established HER2 targeting therapies.   
To date, various preclinical cell-based resistant models have been developed by the 
long term contentious exposure with the drugs, and are used to elucidate the resistance 
mechanism or to discover the drug and/or combination therapy approaches to overcome 
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the refractory tumors[47]. However, the resistant models established in vitro by long 
exposure with the antibodies based drugs may have different the characteristics compared 
to the resistant tumors in clinical settings as following reasons: 1) Cell-based models 
cannot be taken into consideration of the ADCC induced by the HER2-targeting drugs. 
ADCC required immune response in host body. 2) Development process of the resistant 
cell lines by continuous exposure methods in vitro may not reflect the fluctuated transition 
of plasma concentration during the treatment in patients. Therefore, a new model 
mimicking the development process to become resistant to the therapy in clinical setting 
is desired to identify a new therapy effective for the refractory patients to HER2 targeting 
antibodies or ADC, and to elucidate the mechanisms of development of the resistant 
tumors as well. 
In the present study, I confirmed that T-DM1 did not inhibit the phosphorylation of 
HER2 in tumors at the efficacious doses. Therefore, the author hypothesized that mode 
of action of TAS0728 is different from T-DM1. To evaluate the antitumor effect of 
TAS0728 in the resistant tumor to T-DM1, the author has established the resistant models 
by periodic administration of HER2 targeting ADC in vivo. And then, we evaluated the 
TAS0728’s activity in the resistant models. I found that the model still maintain active 
HER2 signaling even after the long term periodic exposure with the drugs in vivo, and are 
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overcome by HER2 signal inhibition with TAS0728, a small molecule HER2 selective 
inhibitor. 
 
4.2 Material and methods 
Phamacodynamics of T-DM1 in mice xenograft model 
Nude mice (BALB/cAJcl-nu/nu) were purchased from CLEA Japan, Inc (Tokyo, Japan). 
Suspensions of NCI-N87 cells were implanted subcutaneously into the side flanks of 6-
week-old male nude mice. Mice were randomized into the control and treatment groups 
(n = 3 per group). T-DM1 was intravenously administered to nude mice. Tumors were 
collected from animals, snap frozen in liquid nitrogen, and stored in a deep freezer for 
pharmacodynamics analysis. Tumor tissues were lysed in lysis buffer containing Sample 
Diluent Concentrate 2 (R&D Systems, Inc., MN, USA), cOmplete Mini Protease Inhibitor 
Cocktail (Roche Diagnostics), and PhosSTOP Phosphatase Inhibitor Cocktail (Roche 
Diagnostics), and processed for Western blot analysis. 
 
In vivo antitumor evaluation in a T-DM1-refractory xenograft model 
Suspensions of cells were implanted subcutaneously into the side flanks of 6-week-old 
nude mice. The tumor volume (TV, mm3) was calculated as the length (mm) × width 
83 
 
(mm)2 / 2. During the treatment period, TV and body weight (BW) were measured twice 
per week. When the TVfinal was smaller than the TVinitial in the treatment group, tumor 
regression was judged to have occurred. As an indicator of changes in BW during the 
dosing period, the BW change (BWC; %) was calculated as 100 – ([BW on each 
measurement day] – [BWinitial]) / (BWinitial), where BWinitial is the body weight on the 
allocation day. Dunnett tests or Aspin-welch t-test were used as a statistical method to 
compare the tumor volume data in the drug-treated and control groups. 
To establish a resistant model to T-DM1, T-DM1 was administered at 10 mg/kg/day 
(q3w, i.v.) in NCI-N87 xenograft model until the tumor regression and the subsequent 
re-growth of tumor were observed despite continued T-DM1 treatment.T-DM1 was 
administered at the dose of 10 mg/kg/day once every 3 weeks for 12 weeks (four doses) 
On Day 85, the tumor volume reached to almost equal volume as the original volume, 
the mice were divided into two groups.Two further doses of T-DM1 were administered 
at the dose of 10 mg/kg (“continued treatment” group), and in the other group, T-DM1 
treatment was switched to TAS0728 administered at the dose of 60 mg/kg for 42 
consecutive days (“switched treatment” group). The antitumor effects in the two groups 
were then compared on Day 43 after dividing the mice into two group..  
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In vivo antitumor evaluation in a PDX model 
The study was conducted using TumorGraft model in Champions oncology,Inc. The 
PDX tumor was derived from a HER2 overexpressed breast cancer patient who showed 
resistance to trastuzumab/pertuzumab-based therapy, T-DM1 and other 
chemotherapies. (Champions oncology. Co., Model#:CTG1171). Immune-
compromised female mice (Harlan; nu/nu) between 5-8 weeks of age are used. 
Beginning Day 0, tumor dimensions are measured twice weekly by digital caliper and 
data including individual and mean estimated tumor volumes (Mean Tumor 
Volume(TV) ± SEM) recorded for each group; tumor volume was calculated using the 
formula: TV= width2 x length x 0.52. TAS0728 was administered at 30 or 60 mg/kg 
for 27 days (q.d., p.o., N=10). Beginning Day 0, animals was observed daily and 
weighed twice weekly using a digital scale; data including individual and mean gram 
weights (Mean We ± SD), mean percent weight change versus Day 0 (%vD0) was 
recorded for each group and %vD0 plotted at study completion. All data collected in 
this study was managed electronically and stored on a redundant server system.  
Animal weight and tumor measurement data were collected and managed 
electronically using Champions Laboratory Information Management System and 
stored on a redundant server system.  
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 4.3 Results  
Phamacodynamic of T-DM1 in mice xenograft model 
Pharmacodynamics analysis at 10 mg/kg/day of T-DM1 in HER2 amplified NCI-N87 
xenograft model revealed that phosphorylation of HER2, AKT, and ERK was not 
decreased compared with that in the control group at tested time point of 1 hour, 24 
hours, 3 days, 7 days, and 14 days after administration.(Figure 4-1)  These results 
suggested that T-DM1 did not inhibit HER2 kinase activity at 10 mg/kg/day in NCI-N87 
model. 
 
Establishment of a T-DM1-refractory xenograft model and in vivo antitumor 
evaluation in a T-DM1-refractory xenograft model   
The ratios of the TVs in the Treatment group (T-DM1 10 mg/kg/day) vs Control group 
(T/C) on Day 22 and Day 33 were 10.7% and 3.6%, respectively (Figure 4-2) . In a 
comparison of the mean TVs between the control and T-DM1 treatment groups, the mean 
TVs in the T-DM1 group on evaluation days 22 and 33 in the induction period of tumor 
regrowth under T-DM1 treatment (Step I as shown in Fugure 4-2) were significantly 
lower than those in the control group (p < 0.0001); thus, T-DM1 was confirmed to exhibit 
86 
 
antitumor effects in the nude mouse NCI-N87 xenograft model. Subsequently, the mean 
TV on Day 85 of Step I (144.26 mm3) in the T-DM1 group was larger than that on Day 
33 (107.90 mm3). As this tumor regrowth was observed during the course of T-DM1 
administration after initial suppression of tumor growth/tumor regression in response to 
the treatment, tumor relapse was judged to have occurred in the mice of the T-DM1 
treatment group on Day 85 (Step I). After switching to TAS0728 treatment (Step II), the 
T/C (TAS0728/T-DM1) ratio in respect of the TV on Day 43 (Day 127 as counted from 
the study baseline) was 25.4% (Figure 4-2). In the comparison of the mean tumor volumes 
between the T-DM1 treated group and TAS0728 treated group in Step II, the mean TV in 
the TAS0728 treated group group on Day 43 (Day 127 from the study baseline) was 
significantly lower than that in the T-DM1 treated group (p = 0.0001), confirming the 
antitumor efficacy of TAS0728 against T-DM1-refractory tumors. As none of the mice 
died, developed any abnormal clinical signs or showed body weight (BW) loss of over 
20%, TAS0728 was judged to have tolerable toxicity (Figure 4-3). 
 Pharmacodymic evaluation revealed that HER2 expression was decreased by T-
DM1 treated group compared with non-treated control group (Figure 4-4). In TAS0728 
treated group, further decrease of phosphorylation level of HER2 was observed.  
Thus, our results showed the potential efficacy of TAS0728 against HER2-positive 
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tumors that have pretreated with T-DM1 and become refractory to T-DM1 treatment. 
 
In vivo antitumor evaluation in a PDX model derived from HER2-positive breast 
cancer patient who heavily pretreated with trastuzumab, pertuzumab, T-DM1, and 
chemotherapies 
The doubling time of the tumor in the Vehicle Control group was 19.9 days. The 
study was completed on Day 27 (28 days). The mean tumor volumes over the duration 
of the study are shown in Figure 4-6. Animals were administered by oral gavage with 
Vehicle Control QDx28 or TAS0728 at 30 mg/kg or 60 mg/kg QD×28. Treatment (n = 
10) with TAS0728 at 30 mg/kg (Mean of tumor volume= 153 ± 27, adjusted p = 0.0043) 
or 60 mg/kg (Mean of TV = 162 ± 27, adjusted p = 0.0056) significantly decreased 
tumor volume compared to that of the Vehicle Control group at Day 27 (Mean of TV = 
483 ± 114) (Figure 4-6). The anti-tumor effects of the 2 TAS0728 dose strengths were 
nearly identical and were not statistically different (adjusted p = 0.9946, one-way 
ANOVA followed by Tukey’s multiple comparison test). The mean animal body weights 
± SEM of the Vehicle Control group and TAS0728 groups are shown in Figure 4-7. 
Both groups gained weight at similar rate. There was no mortality or moribund animal 
in any group. Both doses of TAS0728 were tolerated in this study. 
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Our results showed the potential efficacy of TAS0728 against HER2-positive tumors 
that have heavily pretreated with trastuzumab, pertuzumab, T-DM1, and 
chemotherapies. 
 
4.4 Discussion 
Although those treatments initially induced significant response in clinical settings, 
ultimately become refractory to the therapies. Despite the robust clinical benefit of the 
anti-HER2 antibodies or ADC, the therapy resistance, either de novo or acquired, is an 
important clinical challenge in the management of cancer patients. Therefore, an 
alternative effective therapy to overcome the resistant tumor is required. To date, several 
mechanism of the resistance and the strategy to overcome the drug resistance cancer have 
been discussed based on pre-clinical experiments utilizing the various resistant models 
(Figure 4-8). Most of the models have been established by long time exposure with each 
compound in vitro condition. Given the fact that HER2 targeting antibody and ADC have 
ADCC activity, those established resistant models are not reflect the real patient in clinical 
setting.  
Although T-DM1 showed the significant antitumor efficacy in the HER2-positive 
tumor xenograft model, inhibition of the phosphorylation of HER2 was not observed at 
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their efficacious doses. Therefore, even after the treatment with T-DM1, the tumor still 
has active HER2 signaling pathway in the tumor, and thereby vulnerable for HER2 
signal inhibition.  Indeed, although T-DM1 was no longer effective once the tumor 
started to regrowth during T-DM1 treatment, switching to TAS0728 was effective and 
induced the tumor regression again. On the other hand, decreased expression of HER2 
observed in T-DM1 refractory model when compared to control group suggest that 
resistant mechanism may be due to the HER2 downregulation in tumors. This result is 
also implicated in the previous studies as summarized in Figure 4-7[16]. However, the 
tumors were still sensitive to HER2 kinase inhibition by TAS0728, implicating that 
survival of T-DM1 pretreated, refractory tumors may be addicted to HER2 signaling. 
Although T-DM1 and TAS0728 exert the selective antitumor activity against HER2 
overexpressed tumor, those two drug have distinct mode of action. The antitumor effect 
of T-DM1 is considered to be dependent on ADCC and microtubule assembly 
inhibition[16]. Once T-DM1 binds to HER2 receptors on cancer cells, natural killer 
cells are recruited to initiate ADCC. Moreover, the DM1 is released within the cells and 
cause apoptosis by blocking cell duplication. Therefore, the efficacy of T-DM1 is 
dependent on the copy number of HER2 receptors on cancer cells.  In contrast, 
TAS0728’s mechanism of the antitumor effect is inhibition of HER2 kinase. Therefore, 
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the resistant tumor to T-DM1 was vulnerable to TAS0728.  
In conclusion, TAS0728 has distinct different mode of mechanism from the established 
HER2-targeting antibodies or ADC. Therefore, TAS0728 is expected to be effective for 
refractory patients for the HER2-targeting antibodies or ADC. The data in this chapter is 
planned to be submitted to an international journal in near future.  
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Table 4-1 Patients’s characteristics and pre-treatments of the breast cancer patient used 
for the PDX model are listed from TumorGraft databease of Champions Oncology, 
Inc.(https://championsonclogy.co./)  
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Table 4-2: List of resistant models to T-DM1 from reference [47] . The resistance models 
were established by continuous or cyclical exposure by T-DM1 in vitro.  
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Figure 4-1 Time-course of the in vivo pharmacodynamics activity of T-DM1 on HER2 
and downstream molecules in xenograft tumors. Mice bearing NCI-N87 xenografts were 
administered TAS0728 at 60 mg/kg. At 1, 24 hours, and 3, 7, 14 days after the 
administration of TAS0728, xenograft tumors were collected (n= 3 per group). 
Phosphorylation of HER2-Tyr1196, AKT-Ser473, and ERK1/2-Thr202/Tyr204 and 
expression of cleaved PARP were determined using Western blot analysis. 
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Figure 4-2 Antitumor effect of T-DM1 or TAS0728 in NCI-N87 xenograft model. 
Inhibition of tumor growth in mice bearing NCI-N87 xenografts treated with T-DM1 or 
TAS0728 (n=6 for control group and n=36 for control group in Step 1, n=9 per group in 
Step 2). The treatment switch from T-DM1 to TAS0728 was performed on Day 85. 
TVs(tumor volumes) are represented as the means ± SD.  TV is indicated on a 
logarithmic scale on the vertical axis. *, P<0.0001 compared with the control group in 
the T-DM1 by Aspin-Welch t test. ** P<0.0001 compared with T-DM1 group in TAS0728 
group by Aspin-Welch t test. 
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 Figure 4-3 Body weight changes in NCI-N87 xenograft model treated with T-DM1 or 
TAS0728 (n=6 for control group and n=36 for control group in Step 1, n=9 per group in 
Step 2). The treatment switch from T-DM1 to TAS0728 was performed on Day 85. Data 
are represented as the means ± SD. 
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 Figure 4-4 Pharmacodynamics of TAS0728 or T-DM1 on HER2 and downstream 
molecules in xenograft tumors resistant to T-DM1. Mice bearing NCI-N87 xenografts 
were administered TAS0728 at 60 mg/kg or T-DM1 at 10 mg/kg.  At 1 hour after the 
administration, xenograft tumors were collected (n= 6 for no-treated control. n= 9 for T-
DM1 or TAS0728 treated groups). Phosphorylation of HER2-Tyr1196, HER3-Tyr1289, 
AKT-Ser473, and ERK1/2-Thr202/Tyr204 and expression of BIM isoforms and cleaved 
PARP were determined using Western blot analysis. 
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Fig 4-6 Tumor volume changes in the PDX model treated with TAS0728. Inhibition of 
tumor growth in mice bearing NCI-N87 xenografts treated with TAS0728 for 27 days 
(n=10 per group). *, P<0.01 compared with the control group in the TAS0728 by One-
way ANOVA followed by Dunnett’s multiple comparisons test vs. Vehicle Control. 
TV( tumor volume) was shown as mean ± SEM. 
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Fig 4-7 Body weight change in PDX model (CTG-1171) treated with TAS0728 for 27 
days (n=10 per group). Data is represented as the mean animal body weights ± SEM. 
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Chapter 5: General discussion 
In this study, I aimed to identify a next-generation HER2 inhibitor with both high activity 
and high selectivity for HER2. Accordingly, the author successfully discovered a new 
anti-tumor compound, TAS0728, as a highly selective irreversible inhibitor of HER2 
kinase.  
The functional profiling revealed that TAS0728 has potent antitumor activity through 
the kinase inhibition of HER2. TAS0728 is expected to be effective to HER2 activated 
tumors. The discovery of TAS0728 and the functional characterization of the compound 
can contribute to not only cancer patients but also various research areas. 
To date, no HER2 selective, potent inhibitor has been reported. Although HER2-
targeting antibodies or antibody-drug-conjugate are available for the cancer therapy, those 
drug do not inhibit HER2 kinase activity at the efficacious dose in human.  On the other 
hand, available HER2 inhibitory TKIs are inhibit HER2 kinase as well as EGFR. 
Therefore, in the strict sense, proof of concept of HER2 kinase inhibition against cancer 
have not confirmed yet.  In this study, I obtained the opportunity to confirm proof of 
concept of selective HER2 kinase inhibition by TAS0728.  Asmy hypothesis, 
sustainable inhibition of HER2 without EGFR resulted in significant antitumor effect 
against HER2 activated cancer cells in vitro and in vivo. The data in this study firstly 
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provides POC of selective inhibition of HER2 kinase activity in cancer cells.  
To develop the new therapy to overcome the resistant tumors to conventional therapies, 
a experimental model mimicking tumor in clinical setting is desired. However, given most 
of the models have been established by long time exposure with each compound in vitro 
condition[47], those established resistant models are not reflect the real patient’s immune 
system and DMPK in clinical setting. Therefore, a resistant model were established in 
vivo in this study. The resistant model is valuable to predict whether a new therapy works 
against the resistant patients in clinical setting. The date about the models is now planning 
to publish in an international journal, and may raise a question to the researches using the 
conventional models established in vitro. 
In addition to the contribution to oncology, our discovery of novel anti-tumor compound, 
TAS0728, is anticipated to contribute to the synthetic chemistry field. To date, covalent-
binding kinase inhibitor for HER2 have been challenging due to the high similarity 
between HER2 and EGFR. TAS0728 is an amino-pyrazolopyrimidine class compound, 
which has a distinct chemical structure compared with reported HER2 inhibitory 
compounds, such as afatinib (quinazoline class), lapatinib (quinazoline class), and 
neratinib (cyanoquinoline class) as shown in Figure 5-1[48]. The unique chemical 
structure and the profile of TAS0728 is believed to be valuable information for chemistry 
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researchers to conduct Structure activity relationship analysis to synthesis the new 
compound in future. Therefore, date set of the compound structure information and the 
profile is useful for not only oncology but also medicinal chemistry research field. 
In conclusion, this dissertation will contribute to not only cancer patients but also basic 
oncology research, medicinal chemistry research filed.    
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 Figure 5-1 Compound structures of HER2 TKIs  
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